Sunshine Biopharma Inc (SBFM)

[Kalinn]

Item 1.01 Entry into a Material Definitive Agreement

On November 14, 2014, we entered into a Manufacturing Services Agreement with Lonza Ltd. and Lonza Sales Ltd., (hereinafter jointly referred to as “Lonza”) of Basel, Switzerland (the “Lonza Agreement”), whereby we engaged Lonza to be the manufacturer of our Adva-27a anticancer drug. Lonza has the expertise and worldwide reputation in the evaluation, development and manufacturing of medical products, including new drugs. Lonza has the assets for the manufacturing of our Adva-27a for clinical supply and commercialization from grams to tons scale. The Lonza Agreement is effective November 10, 2014 and has a term of 5 years, and may be extended or terminated earlier as provided in the Lonza Agreement. Delivery of an initial batch for product validation is expected 18 weeks following receipt of the Purchase Order. The cost is estimated to be 145,550 CHF (approximately $139,700 USD).

http://www.sec.gov/Archives/edgar/data/1402328/000135448814005928/sbfm_8k.htm

Camille at his best, this stock is DOA